Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency

Management discussion to include a review of 3-year data from VERTICAL & VISTA Trials

Dr. Bradley Miller featured as a guest speaker

Conference Call and webcast to be held Monday, April 3 at 4:30pm ET

MENLO PARK, Calif., March 23, 2017 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it will host a conference call and webcast on Monday, April 3, 2017 at 4:30pm ET to review its oral and poster presentations from the Endocrine Society's 99th Annual Meeting & Expo (ENDO 2017), being held April 1-4, 2017 in Orlando, Florida.

Versartis has two oral presentations and four posters on somavaratan scheduled during the ENDO 2017 program, including one late-breaker. (Presentation titles and times can be found in the Company’s press release issued on March 2, 2017, located here.) Management will highlight the somavaratan program and new data in pediatric and adult GHD presented during the conference. Dr. Bradley Miller M.D., Ph.D., Associate Professor in the Department of Pediatric Endocrinology at the University of Minnesota Masonic Children's Hospital and a study investigator, will recap his ENDO oral presentation featuring new 3-year data from the VERTICAL and VISTA trials and take questions from call participants. Press releases summarizing the data will be issued on April 3, 2017 prior to the call.

Conference Call and Webcast

The conference call is scheduled for Monday, April 3, 2017 at 4:30pm ET. The dial-in numbers are 877-407-0789 for domestic callers and 201-689-8562 for international callers. A live webcast of the conference call including a slide presentation will be available online from the investor relations page of the Company's corporate website at www.versartis.com.

After the live webcast, the call will remain available on the Versartis website, www.versartis.com, for 90 days. In addition, a telephonic replay of the call will be available until April 17, 2017. The replay dial-in numbers are 844-512-2921 for domestic callers and 412-317-6671 for international callers. Please use the replay conference ID number 13658330.

About Versartis, Inc.

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults.  Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.  For more information on Versartis, visit www.versartis.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2016 and which is on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results may differ materially. Any forward-looking statements that we make in this press release speak only as of the date of this press release and we assume no obligation to update them.

Corporate Communications: 
Christine Labaree
Corporate Affairs
(650) 600-1697
[email protected]

Investors:
David Burke
Director, Investor Relations
(650) 516-2703 
[email protected]